ViRexx presents encouraging early data on HBV vacc

Canadian therapeutics firm ViRexx Medical Corp has reported encouraging results from the laboratory studies on its lead Chimigen Hepatitis B Therapeutic Vaccine candidate.

In ex vivo laboratory studies, the agent produced the desired immune responses in peripheral blood mononuclear cells isolated from patients who are chronically infected by the virus as well as in normal healthy individuals.

"The results are very encouraging, as this is a very important first step in the in the development of an effective Chimigen Hepatitis B Therapeutic Vaccine," said Rajan George, Senior Vice President, R&D.